What is

LONG-ACTING INJECTABLES

– NEW GENERATION, NEW VERSATILITY

Nanexa’s Long-Acting Injectables, including small molecules, proteins and peptides, enable the customized, controlled release of APIs into the bloodstream – increasing compliance, reducing costs and enabling smarter care.

 

LONG-ACTING INJECTABLES

ROBUST, CUSTOMIZABLE, VERSATILE

CUSTOMIZED DEPOT LENGTH

once weekly, monthly or even less frequently

CUSTOMIZED INITIAL DRUG RELEASE

minimizes side effects

enables depot products of potent drugs

INCREASED DRUG LOADS (UP TO 80%)

minimizes injection volumes

enables use of less potent APIs

VERSATILITY

applicable to wide range of APIs

small molecules

biologics, peptides and proteins

STABILITY

coating protects API from degradation during depot time

FLEXIBILITY

subcutaneous or intramuscular administration for systemic exposure

local administration e.g. intratumorally for local effect

Increased compliance

INCREASED COMPLIANCE

By enabling a slower, smother release of API into the bloodstream PharmaShell® reduces the high-concentration peaks which potentially cause severe side effects – so increasing compliance. Poor patient compliance is a major challenge for long-term drug treatment in conditions from oncology to psychiatry.

MULTIPLE MYELOMA – CASE EXAMPLE: NEX-20 is Nanexa’s Long-Acting Injectable formulation of lenalidomide (Revlimid), today’s first-line chemotherapy for MM (Multiple Myeloma), a recurring multi-stage cancer. Patients take Lenalidomide as an oral tablet for 21 days continuously in a 28-day cycle Side effects can be severe – for some patients they can be more disruptive and uncomfortable than their MM symptoms.

Over one third of MM patients have poor compliance: a recent study of 793 patients showed that 38%, over a third, were considered to have poor adherence to lenalidomide. (1) Clin Lymphoma Myeloma Leuk. 2020;20(2):98-104

NEX-20 would replace w21 consecutive daily doses of lenalidomide with a single monthly injection administered in-clinic. The sustained, controlled release – and expected resulting lack of “peaks” in treatment – could significantly reduce side effects, further increasing compliance.

Reduced cost

REDUCED COST

The higher drug load per dose possible with PharmaShell® (from 80 – 90%) enables minimized injection volumes and longer depot formulations – reducing the number of injections and in-clinic visits required.

FROM SEVEN INJECTIONS A MONTH TO ONE
– MDS CASE EXAMPLE:

NEX-18 is Nanexa’s Long-Acting Injectable formulation of azacitidine (Vidaza) – today’s first-line treatment for MDS (Myelodysplastic Syndrome). In its Phase I study, one monthly injection of NEX-18 will replace the current seven consecutive in-clinic injections per month patients currently require.

from 7 injections a month

to 1 injection a month

SMARTER CARE

SMARTER CARE

We can formulate biologics, protein and peptides as well as small molecules, and PharmaShell® can be administered subcutaneously, intramuscularly or intratumorally – offering new versatility for extending depots and crafting smarter therapies and care regimens.

PharmaShell® formulation offers new capabilities for crafting new therapies and enables new IP options for drug developers working with substances heading off-patent.